|Articles|August 1, 2018
- BioPharm International-08-01-2018
- Volume 31
- Issue 8
BioPharm International, August 2018 Issue (PDF)
Click the title above to open the BioPharm International August 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
The Search for Next-Gen Expression Systemsabout 7 years ago
FDA Is Not Playing Games with Biosimilarsabout 7 years ago
Expectations for Residual Impurity Analysis Continue to Riseabout 7 years ago
E&L Risk Assessment for Biologic Drug Productsabout 7 years ago
Submitting Extractables and Leachables Data to Regulatorsabout 7 years ago
A New Paradigm in Drug Developmentabout 7 years ago
Maintaining Cell Line Integrityover 7 years ago
FDA Seeks to Revive Quality Metrics InitiativeNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
4
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
5
